Search results

• 2022

  Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

  Mahil, S. K., Bechman, K., Raharja, A., Domingo-Vila, C., Baudry, D., Brown, M. A., Cope, A. P., Dasandi, T., Graham, C., Khan, H., Lechmere, T., Malim, M. H., Meynell, F., Pollock, E., Sychowska, K., Barker, J. N., Norton, S., Galloway, J. B., Doores, K. J. & Tree, T. & 1 others, Smith, C. H., Jan 2022, In: The Lancet Rheumatology. 4, 1, p. e42-e52

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Immunosuppressive Treatment 100%
  • Cohort Analysis 100%
  • COVID-19 Vaccine 100%
  • Immunosuppression 100%
  • Immunogenicity 100%
  67 Citations (Scopus)

  101 Downloads (Pure)
• 2021

  Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

  McKenzie, D. R., Muñoz-Ruiz, M., Monin, L., Alaguthurai, T., Lechmere, T., Abdul-Jawad, S., Graham, C., Pollock, E., Graham, R., Sychowska, K., Seow, J., Tremain, C., Gousis, C., Domingo-Vila, C., Cooper, J., Vidler, J., Owczarczyk, K., Swampillai, A., Kristeleit, H. & Malim, M. H. & 8 others, Fields, P., Patten, P. E. M., Papa, S., North, B. V., Tree, T., Doores, K. J., Hayday, A. C. & Irshad, S., 8 Nov 2021, In: CANCER CELL. 39, 11, p. 1445-1447 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  32 Citations (Scopus)